Chattem R&D
This article was originally published in The Rose Sheet
Executive Summary
Health and beauty aids manufacturer will break ground for $2 mil., 10,000 sq.-ft. research and development facility in Chattanooga, Tenn. in February, company announces. Research facility, which is slated for completion by end of calendar year, will be dedicated to creating line extensions for existing products, according to President, Chief Operating Officer Alec Taylor. Gold Bond sales are expected to be $40 mil.- $42 mil. in 2002, and pHisoderm annual sales are expected to be in $15 mil.-$17 mil. range, Taylor reports during 1presentation at Banc of America Securities Equity and High Yield Research Household Products Conference Jan. 10...
You may also be interested in...
Chattem Gold Bond, pHisoderm Extensions To Launch In Coming Months
Chattem is gearing up to launch a slew of new product line extensions within the next few months as its decision to increase its investment in R&D over the past two years begins to pay dividends
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.